Kfar Saba, Israel, May 25, 2021
Colospan is pleased to announce that Clalit HMO has executed a purchasing code for the CG-100 intraluminal bypass device.
This step will make the CG-100 available at all of Clalit’s hospitals and help transform the lives of rectal cancer patients as well as save resources to the healthcare system.
The agreement was finalized after an extensive economic and clinical evaluation of the CG-100 device in over 75 rectal cancer patients.
Clalit Health services is the largest HMO in Israel, covering 5 million customers holding 52% market share.
Clalit owns 14 hospitals (30% of Israel’s hospital beds) with a 10 Billion $ budget.
An agreement by such a major group like Clalit is a significant validation of the CG-100’s value proposition.